BLPH - Bellerophon Therapeutics, Inc.
| Previous Close | 0.5900 |
| Open | 0.5900 |
| Bid | 0.6000 x 1000 |
| Ask | 0.6300 x 1100 |
| Day's Range | 0.5900 - 0.6400 |
| 52 Week Range | 0.4700 - 3.3000 |
| Volume | 431,783 |
| Avg. Volume | 276,668 |
| Market Cap | 43.466M |
| Beta (3Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0350 |
| Earnings Date | Aug 7, 2019 - Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- GlobeNewswire•3 days ago
Bellerophon to Host Key Opinion Leader Meeting Focused on Pulmonary Hypertension Associated with Interstitial Lung Disease
Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will host a Key Opinion Leader (KOL) lunch meeting focused on Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) on Wednesday, May 29, 2019, from 12:00 – 1:30 PM ET in New York City. The meeting will feature a presentation by Steven D. Nathan, M.D., F.C.C.P., from Inova Fairfax Hospital, who will discuss the current treatment landscape and unmet medical need for patients with PH-ILD.
- GlobeNewswire•4 days ago
Bellerophon Presents Additional Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference
Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, presented additional data from Cohort 1 of its ongoing Phase 2/3 randomized, double-blind, placebo-controlled clinical study (iNO-PF) of INOpulse® for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) as a late-breaking oral presentation at the American Thoracic Society (ATS) 115th International Conference in Dallas. The ability of INOpulse to improve moderate to vigorous physical activity, or MVPA, as well as other activity parameters, such as overall activity and caloric expenditure, is a significant finding,” said Dr. Nathan.
- Benzinga•7 days ago
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Biotech stocks came under pressure this week along with the broader market, which succumbed to the negative sentiment generated by U.S.-China trade tensions. However, they recouped some of these losses, ...
- GlobeNewswire•12 days ago
Bellerophon to Present Additional Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference
Results to be Presented in Late-Breaking Abstract as an Oral Presentation Company will Also Present a Corporate Overview and Update on its PH-ILD Program at Respiratory.
- Associated Press•16 days ago
Bellerophon Therapeutics: 1Q Earnings Snapshot
The Warren, New Jersey-based company said it had a loss of 1 cent per share. Earnings, adjusted for pretax expenses, came to 1 cent per share. The company's shares closed at 65 cents. A year ago, they ...
- GlobeNewswire•16 days ago
Bellerophon Provides Business Update and Reports First Quarter 2019 Financial Results
WARREN, N.J., May 09, 2019 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a.
- Simply Wall St.•22 days ago
What Kind Of Shareholders Own Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) should be aware of the most powerful s...
- GlobeNewswire•2 months ago
Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
FDA Agrees to Primary Endpoint of Change in Moderate to Vigorous Physical Activity from Baseline to Week 16, Measured by Actigraphy FDA Also Agrees on Modification of Ongoing.
- Simply Wall St.•2 months ago
Did Changing Sentiment Drive Bellerophon Therapeutics’s (NASDAQ:BLPH) Share Price Down A Painful 76%?
It's not possible to invest over long periods without making some bad investments. But really big losses can really drag down an overall portfolio. So take a moment to sympathizeRead More...
- Associated Press•2 months ago
Bellerophon Therapeutics: 4Q Earnings Snapshot
The Warren, New Jersey-based company said it had a loss of 2 cents per share. For the year, the company reported net income of $2.8 million, or 34 cents per share, swinging to a profit in the period. The ...
- GlobeNewswire•2 months ago
Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
WARREN, N.J., March 14, 2019 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a.
- GlobeNewswire•4 months ago
Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients
Actigraphy is Being Utilized to Evaluate Multiple Clinically Meaningful Activity Parameters in the Ongoing INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary.
- GlobeNewswire•4 months ago
Bellerophon Announces Closing of $7 Million Public Offering of Common Stock
Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the closing and funding of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.70 per share, less underwriting discounts and commissions. The Company has also granted the underwriter a 45-day option to purchase up to an additional 1,500,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The Company’s Chairman, Jonathan M. Peacock, and directors Naseem Amin and Ted Wang each purchased shares in the offering. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are $7 million, assuming no exercise of the underwriter’s option to purchase additional shares.
- GlobeNewswire•4 months ago
Bellerophon Announces Pricing of $7 Million Public Offering of Common Stock
Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.70 per share, less underwriting discounts and commissions. The Company also granted the underwriter a 45-day option to purchase up to an additional 1,500,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. Bellerophon expects to receive aggregate gross proceeds of $7 million from the offering, assuming no exercise of the underwriter’s option to purchase additional shares.
- GlobeNewswire•4 months ago
Bellerophon Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Bellerophon also intends to grant the underwriter a 45-day option to purchase additional shares of its common stock equal to 15% of the shares to be sold in the offering to cover over-allotments, if any. Bellerophon intends to use the net proceeds from this offering to fund working capital and other general corporate purposes and pursuit of our other research and development efforts. A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (“SEC”) and was declared effective on July 6, 2018.
- GlobeNewswire•5 months ago
Bellerophon Announces Top-line Results from Cohort 1 of the INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
WARREN, N.J., Jan. 07, 2019 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced.
- GlobeNewswire•6 months ago
Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•6 months ago
DBV Technologies Appoints Daniel Tassé as Chief Executive Officer
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq: DBVT), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has unanimously appointed Daniel Tassé as its Chief Executive Officer (CEO) effective November 29, 2018. Dr. Pierre-Henri Benhamou, who co-founded the Company in 2002, will retire as CEO and serve as Non-Executive Chairman of the Board.
- Associated Press•7 months ago
Bellerophon Therapeutics: 3Q Earnings Snapshot
On a per-share basis, the Warren, New Jersey-based company said it had profit of 10 cents. Earnings, adjusted for non-recurring costs, came to 18 cents per share. The company's shares closed at 90 cents. ...
- GlobeNewswire•7 months ago
Bellerophon Provides Business Update and Reports Third Quarter 2018 Financial Results
WARREN, N.J., Nov. 07, 2018 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a.
- ACCESSWIRE•8 months ago
3 Biotech & Marijuana Stocks to Pay Attention to this Quarter
GTBiopharma (GTBP), for instance has been building a biopharmaceutical pipeline targeting everything from pain management to cancer treatments. This therapy targets cancer cells expressing the CD19 receptor and/or CD22 receptors, which includes B-cell leukemias and lymphomas and has a modified form of diphtheria toxin (DT390) as its cytotoxic drug payload. After OXS-1550 binds to cancer cells, it is taken in by the cancer cells and subsequently deploys its cytotoxic diphtheria toxin payload, which inhibits protein synthesis and kills the cancer cells.
- ACCESSWIRE•9 months ago
Today’s Research Reports on Stocks to Watch:Tesla and Bellerophon Therapeutics
NEW YORK, NY / ACCESSWIRE / August 20, 2018 / Tesla shares were hammered on Friday after CEO Elon Musk revealed to the New York Times that the stress of his job is getting to him. Shares of Bellerophon Therapeutics saw unusual activity, climbing over 20% despite any news. Tesla, Inc. shares plummeted nearly 9% on Friday.
- Benzinga•10 months ago
The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on Aug. 7) Akcea Therapeutics Inc (NASDAQ: AKCA )(reacted to Q2 earnings ...
